Capital and Coast District Health Board logo

Heads Up

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants with Moderate to Severe Atopic Dermatitis

This study is not yet recruiting participants.

Primary Objective: This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

Principal Investigator: Gerhard Eichhoff

Study Coordinator: Bri Boljonis

Trial Website: https://clinicaltrials.gov/ct2/show/NCT03738397

Last updated 25 November 2019.